zurück

Preparation of live, attenuated varicella-zoster virus (Oka/Merck strain)

Subject:

  • Active Substance: Preparation of live, attenuated varicella-zoster virus (Oka/Merck strain)
  • Name: Zostavax®
  • Therapeutic area: Treatment of Herpes Zoster
  • Pharmaceutical company: MSD SHARP & DOHME GMBH

 

Time table:

  • Publication of final assessment: 17.09.2013

 

Assessment information:

  • Title: Zostavax for the prevention herpes zoster and postherpetic nostalgia
  • Author/Co-Author: CVZ (Netherlands), UCSC Gemelli (Italy)
  • Dedicated Reviewers: HAS (France), DPA/MoH Malta (Malta), RIZIV-INAMI (Belgium), BIQG/GÖG (Austria), MoH Czech (Czech Republic), Veneto/CRUF (Italy), DGFPS MSPSI (Spain)

G-BA assessment not available
Reason: First launch of Zostavax® was in 2006 (pre-AMNOG).